NCT00235820

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 271 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	adalimumab	40 mg every other week following an 80 mg dose
DRUG	MTX	MTX 7.5 to 25 mg once weekly
DRUG	placebo adalimumab, placebo MTX	placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)

Timeline

• Start date: 2005-07-01
• Primary completion: 2006-05-01
• First posted: 2005-10-12
• Last updated: 2008-07-17

Locations

1 site across 1 country: United States